Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The Australian Liver FaIlurE (ALFIE) trial, a multicentre, randomised controlled trial, assessed the efficacy of a nurse-coordinated model of care to reduce liver-related emergency admissions (LREAs) in patients with decompensated cirrhosis. The model of care was delivered by a specialist nurse, including intensive postdischarge monitoring, linkage to multidisciplinary care, rapid access to care pathway, enhanced education and self-management support.
Objective: To examine the experiences of participants and practitioners in the ALFIE trial to understand its impact, barriers and areas for improvement.
Design And Setting: A qualitative semistructured interview analysis nested within the ALFIE trial.
Participants: A purposeful sample of 15 patients, 14 controls and 12 staff.
Intervention: Thematic analysis of interview transcripts.
Results: Interventional participants and the nurses perceived the care provided as personalised, holistic and continuous. The intervention enabled the development of robust therapeutic relationships and trust that promoted participant engagement and risk factor modification. It helped intervention participants navigate the busy hospital system. The control participants desired more education and a personal contact to deal with emergencies. With respect to the intervention, nurses felt that their support helped reduce LREAs and improve care, but it was overwhelming. A number of barriers and systemic issues were identified. Suggestions for improvement of the intervention model included increased staffing, improved mental health support and communication pathways with primary care practitioners.
Conclusions: The ALFIE trial was well received by nurses and participants. It met the needs of intervention participants and the health system through easy-to-navigate, personalised, holistic and ongoing care. The study identified barriers and systemic improvement areas.
Trial Registration Number: ACTRN12617001293358.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831275 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2024-089666 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
Lancet Oncol
July 2025
Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Background: Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic soft-tissue metastases that has progressed on an androgen receptor pathway inhibitor (ARPI) have a poor prognosis with few treatment options. We aimed to assess efficacy and safety of cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties, plus the PD-L1 inhibitor atezolizumab in these patients.
Methods: CONTACT-02 is an open-label, randomised, phase 3 study that enrolled patients at 184 sites across 24 countries (in Europe, North America, Asia-Pacific, and Latin America).
Terlipressin-Associated Complete Heart Block.
ACG Case Rep J
April 2025
Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Terlipressin has been recently approved in the United States to treat hepatorenal syndrome, a feared complication of both acute and chronic liver diseases. Side effects of the medication have been studied through clinical trials and the precedent use in Europe, as well as extrapolation from its analog vasopressin. As its use is becoming more prevalent, unforeseen complications have arisen.
View Article and Find Full Text PDFA qualitative enquiry into participants' and practitioners' experiences in the Australian Liver FaIlurE trial.
BMJ Open
February 2025
Hepatology and Liver Transplantation Medicine Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Background: The Australian Liver FaIlurE (ALFIE) trial, a multicentre, randomised controlled trial, assessed the efficacy of a nurse-coordinated model of care to reduce liver-related emergency admissions (LREAs) in patients with decompensated cirrhosis. The model of care was delivered by a specialist nurse, including intensive postdischarge monitoring, linkage to multidisciplinary care, rapid access to care pathway, enhanced education and self-management support.
Objective: To examine the experiences of participants and practitioners in the ALFIE trial to understand its impact, barriers and areas for improvement.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
J Clin Oncol
March 2025
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
Article Synopsis
- The study compared the combination of lenvatinib and pembrolizumab (len + pembro) with traditional chemotherapy for advanced or recurrent endometrial cancer (aEC) in patients who had not previously been treated.
- Results showed that while len + pembro did not statistically outperform chemotherapy in terms of progression-free survival (PFS) or overall survival (OS), it offered similar outcomes, indicating noninferiority.
- The trial involved 842 patients and found median PFS and OS were comparable between the two treatment groups, suggesting len + pembro could be an effective alternative to chemotherapy for this cancer type.
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.
Obes Rev
January 2025
Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, Louisiana, USA.
The rapid and widespread clinical adoption of highly effective incretin-mimetic drugs (IMDs), particularly semaglutide and tirzepatide, for the treatment of obesity has outpaced the updating of clinical practice guidelines. Consequently, many patients may be at risk for adverse effects and uncertain long-term outcomes related to the use of these drugs. Of emerging concern is the loss of skeletal muscle mass and function that can accompany rapid substantial weight reduction; such losses can lead to reduced functional and metabolic health, weight cycling, compromised quality of life, and other adverse outcomes.
View Article and Find Full Text PDF